- Last Close 9.32
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Growth
- Day Range 8.95 – 9.36
- Year Range 7.36 – 15.24
- Market Cap 753.4076 Mil
- Volume / Avg 960,729.0 / 1.0 Mil
- Price / Sales —
- Price / Book 5.19
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis AVXL
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile AVXL
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
New York, NY, 10111
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Anavex Life Sciences Corp
Abeona Therapeutics Inc
vTv Therapeutics Inc Class A
Lixte Biotech Holdings Inc
|+$0.36 (4.02%)||−$0.07 (2.18%)||+$0.08 (10.97%)||+$0.03 (4.41%)|
|753.41 Mil||58.96 Mil||69.65 Mil||11.83 Mil|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Anavex Life Sciences Corp Stock
No. AVXL does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
AVXL’s market cap is 753.41 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
AVXL’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
AVXL’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare AVXL’s historical performance against its industry peers and the overall market.